Correlation Between Moleculin Biotech and Akari Therapeutics
Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Moleculin Biotech and Akari Therapeutics PLC, you can compare the effects of market volatilities on Moleculin Biotech and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Akari Therapeutics.
Diversification Opportunities for Moleculin Biotech and Akari Therapeutics
0.49 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Moleculin and Akari is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Akari Therapeutics go up and down completely randomly.
Pair Corralation between Moleculin Biotech and Akari Therapeutics
Given the investment horizon of 90 days Moleculin Biotech is expected to under-perform the Akari Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Moleculin Biotech is 1.09 times less risky than Akari Therapeutics. The stock trades about -0.06 of its potential returns per unit of risk. The Akari Therapeutics PLC is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest 974.00 in Akari Therapeutics PLC on November 2, 2024 and sell it today you would lose (842.00) from holding Akari Therapeutics PLC or give up 86.45% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 99.8% |
| Values | Daily Returns |
Moleculin Biotech vs. Akari Therapeutics PLC
Performance |
| Timeline |
| Moleculin Biotech |
| Akari Therapeutics PLC |
Moleculin Biotech and Akari Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Moleculin Biotech and Akari Therapeutics
The main advantage of trading using opposite Moleculin Biotech and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.| Moleculin Biotech vs. Pulmatrix | Moleculin Biotech vs. Cyclacel Pharmaceuticals | Moleculin Biotech vs. Akari Therapeutics PLC | Moleculin Biotech vs. Bio Path Holdings |
| Akari Therapeutics vs. Armata Pharmaceuticals | Akari Therapeutics vs. Anebulo Pharmaceuticals | Akari Therapeutics vs. Processa Pharmaceuticals | Akari Therapeutics vs. Salarius Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Complementary Tools
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |